Regeneron Pharmaceuticals (REGN) - Stock & Dividends

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US75886F1075

Regeneron Pharmaceuticals, Inc., listed on the NASDAQ under the ticker symbol REGN, is a global pharmaceutical company known for its discoveries, inventions, and development of medicines catering to a wide range of diseases.

Among its well-known products is EYLEA injection, used for treating wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy, neovascular glaucoma, and other eye-related conditions. Additionally, Dupixent injection targets atopic dermatitis and asthma, while Libtayo injection is designed for treating cutaneous squamous cell carcinoma.

Regeneron Pharmaceuticals also offers Praluent injection for addressing cholesterol-related issues and cardiovascular diseases and the critical REGEN-COV for tackling the COVID-19 virus. Furthermore, Kevzara solution is available for rheumatoid arthritis, Inmazeb for infections caused by Zaire ebolavirus, and ARCALYST for cryopyrin-associated periodic syndromes.

Headquartered in Tarrytown, New York, Regeneron Pharmaceuticals was established in 1988. The company's extensive portfolio includes medications for eye diseases, allergies, cardiovascular conditions, infectious diseases, and rare disorders, alongside ongoing research in oncology, pain management, and hematological issues.

For more information about Regeneron Pharmaceuticals, visit their official website at https://www.regeneron.com.

AI improved, may contain errors or wrong assumptions

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for Regeneron Pharmaceuticals (REGN) - Stock & Dividends

REGN Stock Overview

Market Cap in USD 104,613m
Sector Healthcare
Industry Biotechnology
GiC SubIndustry Biotechnology
TER 0.00%
IPO / Inception 1991-04-02

REGN Stock Ratings

Fundamental 6.30
Dividend -
Growth 5y 7.55
Rel. Performance vs Sector 0.67
Analysts 3.96
Fair Price Total Ret. 1022.74
Fair Price DCF 968.26

REGN Dividends

Yield 12m 0.00%
Yield on Cost 5y 0.00%
Dividends CAGR 5y 0.00%
Payout Consistency 0.0%

REGN Growth Ratios

Growth 12m 28.19%
Growth Correlation 12m 52%
Growth Correlation 3m 81%
CAGR 5y 17.85%
CAGR / Mean Drawdown 1.47
Sharpe Ratio 12m 1.05
Alpha vs SP500 12m 10.36
Beta vs SP500 5y weekly 0.51
CAPM 6.61%
Average Daily Range 2m 1.87%
Regime Oscillator 85.28
Volatility GJR Garch 1y 25.01%
Price / SMA 50 6.71%
Price / SMA 200 20.04%
Current Volume 486k
Average Volume 20d 503.1k

External Links for REGN Stock

News
Wall Street JournalBenzingaYahoo Finance
Tweets
X (Twitter)Stocktwits
Fund Manager Positions
DataromaStockcircle
What is the price of REGN stocks?
As of February 29, 2024, the stock is trading at USD 987.61 with a total of 486,000 shares traded.
Over the past week, the price has changed by +3.65%, over one month by +3.33%, over three months by +23.28% and over the past year by +30.33%.
Why is REGN stock down?
Check with which Index or Commodity REGN has the highest Correlation, do they have a common driver?
Review the Fundamentals to find weaknesses (Debt, low returns). Check the Performance of the Peer-Group to find out, if the entire sector is under pressure.
Period Return REGN Return S&P 500
1 Month 3.33% 3.05%
3 Months 23.28% 11.73%
12 Months 30.33% 29.22%
What is the forecast for REGN stock price target?
According to ValueRays Forecast Model, REGN Regeneron Pharmaceuticals will be worth about 1124.7 in February 2025. The stock is currently trading at 987.61. This means that the stock has a potential upside of +13.88%.
Issuer Forecast Upside
Wallstreet Target Price 1020.1 3.3%
Analysts Target Price 912.5 -7.6%
ValueRay Target Price 1124.7 13.9%

The Evolution and Market Presence of Regeneron Pharmaceuticals Inc

History and Development

Regeneron Pharmaceuticals Inc, a name synonymous with innovation in biotechnology, embarked on its journey in 1988. Founded by Leonard Schleifer and George Yancopoulos, its mission was to harness the power of science to combat serious diseases. Over the decades, Regeneron has stayed true to its roots, focusing intensely on developing drugs through rigorous scientific methods and groundbreaking genetic research.

Core Business

At its core, Regeneron specializes in developing, manufacturing, and marketing treatments for serious medical conditions. This includes diseases such as age-related macular degeneration, cancer, and asthma. Their innovative approach, particularly in the realm of monoclonal antibodies, has led to the development of some ground-breaking medications. EYLEA, an injection for certain eye diseases, and Dupixent, used for asthma and dermatological conditions, are among their most successful products.

Side Businesses and Collaborations

While focused on drug development, Regeneron also leverages collaborations and partnerships to broaden its reach. They've worked alongside international pharmaceutical giants, enhancing their drug pipeline and accelerating development. Regeneron's commitment to research has also propelled them into genomics, with their Regeneron Genetics Center undertaking one of the world's largest genetics sequencing efforts for drug discovery and personalized medicine.

Current Market Status

As of 2023, Regeneron Pharmaceuticals Inc stands as a major player in the biotech industry. With a robust pipeline and strong sales from key products like EYLEA and Dupixent, Regeneron continues to exhibit financial growth. Despite market fluctuations and competitive pressures, their focus on innovative therapies and strategic alliances drives their ongoing success and resilience in a complex market.